GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BML Inc (OTCPK:BMLKF) » Definitions » EBITDA Margin %

BML (BMLKF) EBITDA Margin % : 8.07% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is BML EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. BML's EBITDA for the three months ended in Dec. 2023 was $19.7 Mil. BML's Revenue for the three months ended in Dec. 2023 was $243.8 Mil. Therefore, BML's EBITDA margin for the quarter that ended in Dec. 2023 was 8.07%.


BML EBITDA Margin % Historical Data

The historical data trend for BML's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BML EBITDA Margin % Chart

BML Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.64 19.05 30.19 19.11 11.83

BML Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.64 7.84 7.10 8.07 4.74

Competitive Comparison of BML's EBITDA Margin %

For the Diagnostics & Research subindustry, BML's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BML's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BML's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where BML's EBITDA Margin % falls into.



BML EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

BML's EBITDA Margin % for the fiscal year that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=108.978/920.874
=11.83 %

BML's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=19.676/243.823
=8.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BML  (OTCPK:BMLKF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


BML EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of BML's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BML (BMLKF) Business Description

Traded in Other Exchanges
Address
5-21-3 Sendagaya, Shibuya-ku, Tokyo, JPN, 1510051
BML Inc provides laboratory testing services in Japan through a network of regional facilities. Its core clinical testing business provides a range of general and specialty laboratory tests, as well as microbiological tests that can be used for applications like food sanitation and environmental analysis. BML often uses automated systems to process and analyze these test samples. In addition to its clinical testing business, BML also has a medical information systems business and a genome-related business. The medical information systems business provides electronic medical charts and information systems that can be used in conjunction with its laboratory tests. The genome business provides gene analysis services.